Niamh Madigan | 05/30/2012
With a population of 1.9 billion and a multi-medicine model, the reporting of adverse reactions in medicine in India is crucial. The pharmacovigilance programme was launched in India in 2010 to provide education about drug safety. Dr. Y.K Gupta, Co-ordinator of the national pharmacovigilance programme, India tells Pharma IQ how to overcome the obstacles to implemeting such a programme.
Have Your Say
Rate this feature and give us your feedback in...
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
GenAI Life Science & Health 2025
September 1 - 3, 2025
Berlin, Germany
Register Now |
View Agenda |
Learn More
DigIT Pharma AI Commercial Excellence & Health 2025
September 1 - 3, 2025
Palace Hotel Berlin, Germany
Register Now |
View Agenda |
Learn More